I have been able to parse through Biogen's presentation of the results of its clinical trial for Alzheimer's disease:
They are as follows: Significant reduction in amyloid plaques with 3, 6, and 10 mg at 26 weeks
Significant reduction in amyloid plaques at 54 weeks with 3 and 10 mg (results for 6 mg not released yet)
Significant improvement in cognition (as measured by MMSE scores) at 54 weeks in 3 and 10 mg
Significant improvement in cognition and function (as measured by CDR-SB) for 10 mg group only.
Results for 6 mg group still pending
No results for cognition/function were reported for 26 weeks; the likely reason Biogen omitted this information was that they were not significant.
http://www.thestreet.com/story/1308...ers-and-the-biotech-mania-is-it-a-bubble.html
In the 10mg, 35 percent of the participants with the Apoe4 gene dropped out due to adverse effects. It would be helpful to know when they dropped out because if it were between 26 and 54 weeks that would bring into question how significant the results for the 10 mg group actually were.
This was supposed to be a study showing how a particularly effective amyloid antibody was at reducing cognitive decline in early Alzheimer's disease, but irony of ironies it may have just proved the opposite.
- Forums
- ASX - By Stock
- Amyloid, cognition, Biogen
I have been able to parse through Biogen's presentation of the...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.19M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $27.94K | 6.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 57489001 | 48 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
47 | 58163299 | 0.004 |
75 | 84508146 | 0.003 |
19 | 29345125 | 0.002 |
16 | 81865102 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 57455001 | 47 |
0.006 | 17905330 | 28 |
0.007 | 9788861 | 19 |
0.008 | 8393109 | 16 |
0.009 | 4646078 | 9 |
Last trade - 16.10pm 28/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 20524121 | ||
Last updated 15.46pm 28/03/2024 ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online